JPMorgan raised the firm’s price target on Cogent Biosciences (COGT) to $67 from $65 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Positive Clinical Trial Results
- Cogent Biosciences price target raised to $48 from $45 at Jefferies
- Cogent Biosciences announces results of APEX trial of bezuclastinib
- Cogent Biosciences presents full SUMMIT results of bezuclastinib
- Cogent Biosciences Completes $230M Convertible Notes Offering